Abstract
Introduction In an attempt to capture clinically meaningful cognitive decline in early dementia, we developed the Cognitive-Functional Composite (CFC). We investigated the CFC’s sensitivity to decline in comparison to traditional clinical endpoints.
Methods This longitudinal construct validation study included 148 participants with subjective cognitive decline, mild cognitive impairment or mild dementia. The CFC and traditional tests were administered at baseline, 3, 6 and 12 months. Sensitivity to change was investigated using linear mixed models and r2 effect-sizes.
Results CFC scores declined over time (β=−.16,p<.001), with steepest decline observed in mild Alzheimer’s dementia (β=−.25,p<.001). The CFC showed medium-to-large effect-sizes at succeeding follow-up points (r2=.08–.42), exhibiting greater change than the Clinical Dementia Rating scale (r2=.02–.12). Moreover, change on the CFC was significantly associated with informant reports of cognitive decline (β=.38,p<.001).
Discussion By showing sensitivity to decline, the CFC could enhance the monitoring of disease progression in dementia research and clinical practice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUmc Fonds. The present study is supported by a grant from Memorabel (grant no. 733050205), which is the research program of the Dutch Deltaplan for Dementia.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon reasonable request.
List of Abbreviations
- AC
- Alzheimer Center Amsterdam
- AD
- Alzheimer’s Disease
- ADAS-Cog
- Alzheimer’s Disease Assessment Scale - Cognitive subscale
- ADCOMS
- Alzheimer’s Disease Composite Score
- ADCS-ADL
- Alzheimer’s Disease Cooperative Study - Activities of Daily Living Inventory
- AES
- Apathy Evaluation Scale
- A-IADL-Q
- Amsterdam IADL Questionnaire
- Catch-Cog
- Capturing Changes in Cognition
- CC
- Cognitive Composite
- CDR-SB
- Clinical Dementia Rating scale – Sum of Boxes
- CFC
- Cognitive Functional Composite
- CFI
- Cognitive Function Instrument
- CFT
- Category Fluency Test
- COWAT
- Controlled Oral Word Association Test
- DLB
- Dementia with Lewy Bodies
- DSST
- Digit Symbol Substitution Test
- EDI
- Centre for Dementia Prevention, Edinburgh
- EM
- Episodic memory
- EMA
- European Medicine Agency
- EMC
- Erasmus Medical Center
- EF
- Executive functioning
- FDA
- Food and Drug Administration
- IADL
- Instrumental Activities of Daily Living
- IRT
- Item Response Theory
- LMM
- Linear Mixed Models
- MCI
- Mild Cognitive Impairment
- MMSE
- Mini-Mental State Examination
- SCD
- Subjective Cognitive Decline
- UMCG
- University Medical Center Groningen
- WM
- Working Memory.
